-+ 0.00%
-+ 0.00%
-+ 0.00%

INVIVYD ANNOUNCES REVOLUTION PROGRAM PROGRESS AND ADVANCEMENT OF NOVEL, POTENTIAL FIRST- AND BEST-IN-CLASS MEASLES MONOCLONAL ANTIBODY CANDIDATE VMS063 FOR TREATMENT AND PREVENTION OF MEASLES

Reuters·04/09/2026 11:01:13

Please log in to view news